Overview of the LUX-Lung Clinical Trial Program of Afatinib for Non-Small Cell Lung Cancer
A partir des données de 8 essais cliniques, cette étude analyse l'efficacité de l'afatinib, un inhibiteur de tyrosine kinase anti-EGFR, en traitement de première, seconde et troisième ligne d'un cancer du poumon non à petites cellules
Tyrosine kinase inhibitors (TKIs) have emerged as first-line treatment for the management of epidermal growth factor receptor (EGFR)–mutated advanced non–small cell lung cancer (NSCLC). Erlotinib and gefitinib were the initial TKIs to be approved for lung cancer and showed improved response rates compared with chemotherapy. Afatinib is an irreversible ErbB family blocker that has also been shown to be active in EGFR-mutated NSCLC. Afatinib has been tested as first-line treatment of advanced NSCLC in the LUX-Lung trial program, as well as in the second- and third-line settings. In this article, we will review the data from the 8 reported LUX-Lung trials.